In a report published Thursday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Regeneron Pharmaceuticals REGN, but removed the $310.00 price target.
In the report, Morgan Stanley noted, “Dupilumab (IL-4R antibody) achieved statistical significant reductions of atopic dermatitis (AD) in PhIIb study: Mean changes in placebo-adj EASI score (AD clearance) were 27% (100mg weekly) - 56% (300mg weekly) compared to 51% (300mg weekly) in PhIIa. Safety appeared clean with incr. in colds and headache (also observed in the asthma studies) higher than placebo as well as injection site reactions (5-9.5% vs 3%). As previously planned, PhIII will start in 2H14.”
Regeneron Pharmaceuticals closed on Wednesday at $310.93.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in